Aristolochic acid nephropathy - still real danger
DOI:
https://doi.org/10.12775/JEHS.2022.12.10.013Keywords
aristolochic acid nephropathy, aristolochic acid, Chinese herbal nephropathy, urinary tract cancerAbstract
Arystolocholic acid nephropathy is chronic kidney disease caused by the use of substances of natural origin that contain arystolocholic acid. The effects of their use are arystolochic acid nephropathies, which include "Chinese Herbs" nephropathy. The course of the disease is very fast, resulting in progression to end-stage renal disease, and in the future it results in the development of urinary tract cancer. That is why it is so important to recognize it early and start treatment. However, due to disease progression, some patients require dialysis and even kidney transplantation. Although the World Health Organization is trying to stop the spread of the use of harmful substances, there are still reports of this nephropathy appearing in some populations. Despite warnings from the Food and Drug Administration regarding the safety of botanicals containing arystolochic acid and its classification as a human carcinogen, products containing it are still available for purchase online. The purpose of the literature review below is to analyze the latest knowledge on aristolochic acid nephropathy and its associated complication.
References
Anandagoda N, Lord GM: Preventing aristolochic acid nephropathy. Clin J Am Soc Nephrol. 2015;10(2):167-8.
Ban TH, Min JW, Seo C i in. Update of aristolochic acid nephropathy in Korea. Korean J Intern Med. 2018 Sep;33(5):961-969. doi: 10.3904/kjim.2016.288.
Bardia A, Nisly NL, Zimmerman MB, i in.: Use of herbs among adults based on evidence-based indications: findings from the National Health Interview Survey. Mayo Clin Proc. 2007 May;82(5):561-6.
Chen D, Tang Z, Luo C i in.: Clinical and pathological spectrums of aristolochic acid nephropathy. Clin Nephrol. 2012;78(1):54-60.
Cosyns JP, Dehoux JP, Guiot Y i in. Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int. 2001 Jun;59(6):2164-73.
Czekalski S, Pawlaczyk K, Drabczyk R.: Przewlekłe cewkowo-śródmiąższowe zapalenie nerek. Interna Szczeklika 2021.
De Broe M.: Balkan endemic nephropathy. Uptodate. 2021.
De Broe M.: Nephropathy induced by aristolochic acid (AA) containing herbs, Uptodate. 2021.
Debelle FD, Vanherweghem JL, Nortier JL.: Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 2008;74(2):158-69.
Gökmen MR, Cosyns JP, Arlt VM, i in.: The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. Ann Intern Med. 2013;158(6):469-77.
Jadot I, Declèves AE, Nortier J, i in.: An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. Int J Mol Sci. 2017 Jan 29;18(2):297.
Jelaković B, Nikolić J, Radovanović Z i in.: Consensus statement on screening, diagnosis, classification and treatment of endemic (Balkan) nephropathy. Nephrol Dial Transplant. 2014 Nov;29(11):2020-7.
Luciano RL, Perazella MA.: Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. Drug Saf. 2015;38(1):55-64.
Nortier J, Pozdzik A, Roumeguere T i in.: Néphropathie aux acides aristolochiques. Nephrol Ther. 2015;11(7):574-88.
Rebhan K, Ertl IE, Shariat SF i in.: Aristolochic acid and its effect on different cancers in uro-oncology. Curr Opin Urol. 2020 Sep;30(5):689-695.
Rouprêt M, Babjuk M, Compérat E i in.: European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol. 2018 Jan;73(1):111-122.
Schmeiser HH, Nortier JL, Singh R i in.: Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer. 2014;135(2):502-7.
Stiborová M, Arlt VM, Schmeiser HH.: Balkan endemic nephropathy: an update on its aetiology. Arch Toxicol. 2016;90(11):2595-2615.
Stiborová M, Arlt VM, Schmeiser HH.: DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer. Int J Mol Sci. 2017;18(10):2144..
Wang D, Li XW, Wang X i in.: Alpha-Actinin-4 is a Possible Target Protein for Aristolochic Acid I in Human Kidney Cells In Vitro. Am J Chin Med. 2016;44(2):291-304.
World Health Organization: WHO traditional medicine strategy: 2014-2023. 2013
Xylinas E, Rink M, Cha EK i in.: Upper Tract Urothelial Carcinoma Collaboration. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2014 Jan;65(1):210-7.
Yang B, Xie Y, Guo M, i in.: Nephrotoxicity and Chinese Herbal Medicine. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1605-1611.
Yang HY, Yang CC, Wu CY i in.: Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. Int J Mol Sci. 2019 Jun 28;20(13):3162.
Yang L, Su T, Li XM i in.: Aristolochic acid nephropathy: variation in presentation and prognosis. Nephrol Dial Transplant. 2012;27(1):292-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Rafał Oleszczuk, Agnieszka M. Grzebalska, Iga Kozińska, Maciej Orczykowski, Anna Oleszczuk
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 686
Number of citations: 0
